Immunogenicity and Safety of Inactivated H1N1 Swine-origin Influenza Monovalent Vaccine in Immunocompromised Children and Young Adults
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study will evaluate the immunogenicity and safety of inactivated H1N1 swine-origin monovalent influenza vaccine in immunocompromised children and young adults.
| Condition |
|---|
|
H1N1 Pandemic Flu |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | Immunogenicity and Safety of Inactivated H1N1 Swine-origin Influenza Monovalent Vaccine in Immunocompromised Children and Young Adults |
- This study will document Seroprotection (a post-vaccine antibody response ≥ an HI titer of 1:40). [ Time Frame: 1.5 years ] [ Designated as safety issue: Yes ]
- This study will document seroconversion rates (a 4-fold or greater rise in HI titer comparing pre- and post-vaccine sera). [ Time Frame: 1.5 years ] [ Designated as safety issue: Yes ]
Biospecimen Retention: Samples With DNA
Blood sample collection will be done according to the description provided in the institutional policy manual. When possible, blood draws will be made through existing implanted catheters. If the research participant does not have a catheter, a peripheral venipuncture will be performed. Serum and whole blood for immune assays will be frozen at -20ºC or in liquid nitrogen until processed in batched assays.
| Enrollment: | 104 |
| Study Start Date: | October 2009 |
| Study Completion Date: | June 2011 |
| Primary Completion Date: | June 2011 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
H1N1 pandemic influenza vaccine recipient
Children and young adults between the ages of 6 months and 21 years and 13 kg or greater in body weight with underlying conditions of cancer, HIV, sickle cell disease or receipt of a stem cell transplant more than a year prior to study entry and who will receive inactivated H1N1 swine-origin monovalent influenza vaccine in the winter/fall of 2009-2010 as part of their routine clinical care.Target total accrual of up to 400 children and young adults stratified based on their underlying diagnosis as follows: 150 children or young adults with cancer, 100 with human immunodeficiency virus (HIV), 100 with sickle cell disease, and 50 with receipt of a stem cell transplant more than a year prior to study entry.
|
Detailed Description:
This is a prospective observational study. This study will not dictate vaccine administration, nor the vaccine product to be used. It will collect data in St Jude patients who will receive the vaccine as part of their clinical care per institutional guidelines. Research participants will receive two doses of inactivated H1N1 swine-origin monovalent influenza vaccine administered 28 days apart as part of clinical care. Each dose contains 15 mcg of hemagglutinin antigen (HA).Follow-up visits will be scheduled 28 days after each dose and at day 208+/- 14 days for blood work. The day of administration of the first vaccine dose is counted as day 0. At each of these visits, blood will be collected to assess for immunogenicity. Research participants will be given a diary card to record symptoms for 28 days . They will be asked to bring this diary back at the next visit. Other vaccine-related adverse events will also be collected by retrospective chart review.
Children and young adults between the ages of 6 months and 21 years and 13 kg or greater in body weight who have an underlying diagnosis of cancer, HIV, sickle cell disease or receipt of a stem cell transplant more than a year prior to study entry and who will receive inactivated H1N1 swine-origin monovalent influenza vaccine in the winter/fall of 2009-2010 as part of their routine clinical care.
Eligibility| Ages Eligible for Study: | 6 Months to 21 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Children and young adults between the ages of 6 months and 21 years and 13 kg or greater in body weight who have an underlying diagnosis of cancer, HIV, sickle cell disease or receipt of a stem cell transplant more than a year prior to study entry and who will receive inactivated H1N1 swine-origin monovalent influenza vaccine in the winter/fall of 2009-2010 as part of their routine clinical care. Stem cell transplant recipients in the first year following their transplant are excluded.
Inclusion Criteria:
- Age 6 months through 21 years of age at the time of entry into the study;
- Body weight of 13 kg or greater at the time of entry into the study;
- Participant is immunocompromised due to cancer, HIV, or sickle cell disease or receipt of a stem cell transplant;
- Participant or participant's parent/legal guardian available by telephone during the course of the study;
- Written informed consent (and assent, if applicable) obtained;
- Potential research participant received or will receive H1N1 swine-origin monovalent influenza vaccine within 24 hours of study entry.
Exclusion Criteria:
- Proven history, by RT-PCR, of H1N1 swine-origin influenza infection prior to study entry;
- Receipt of a stem cell transplant within one year prior to study entry;
- Participation in P1088 study.
Contacts and Locations| United States, Tennessee | |
| St.Jude Children's Research Hospital | |
| Memphis, Tennessee, United States, 38105 | |
| Principal Investigator: | Hana Hakim, MD | St. Jude Children's Research Hospital |
More Information
Additional Information:
No publications provided
| Responsible Party: | St. Jude Children's Research Hospital |
| ClinicalTrials.gov Identifier: | NCT01000571 History of Changes |
| Other Study ID Numbers: | SOVAC |
| Study First Received: | October 19, 2009 |
| Last Updated: | October 5, 2011 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by St. Jude Children's Research Hospital:
|
H1N1 pandemic flu |
Additional relevant MeSH terms:
|
Influenza, Human Orthomyxoviridae Infections RNA Virus Infections |
Virus Diseases Respiratory Tract Infections Respiratory Tract Diseases |
ClinicalTrials.gov processed this record on May 22, 2013